News
MBIO
--
0.00%
--
Mustang Bio to Participate in Three September 2021 Investor Conferences
WORCESTER, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematolog...
GlobeNewswire · 09/09 12:30
BRIEF-Mustang Bio Q2 Loss Per Share $0.16
reuters.com · 08/16 20:47
Mustang Bio Q2 EPS $(0.16) Up From $(0.32) YoY
Mustang Bio (NASDAQ:MBIO) reported quarterly losses of $(0.16) per share. This is a 50 percent increase over losses of $(0.32) per share from the same period last year.
Benzinga · 08/16 20:07
-- Earnings Flash (MBIO) MUSTANG BIO Reports Q2 Loss $-0.16
MT Newswires · 08/16 16:10
Mustang Bio, Mayo Clinic Join Forces On New CAR T Tech In Tumor Settings
Benzinga · 08/13 14:03
BRIEF-Mustang Bio Inc Collaborates with Mayo Clinic on Novel CAR T Technology
reuters.com · 08/12 20:49
Mustang Bio to Collaborate with Mayo Clinic on CART T Therapy Administration Technology
MT Newswires · 08/12 17:21
Bluebird bio’s setback hurts AVROBIO and others focused on lentiviral gene therapies
bluebird bio (BLUE -25.0%) has lost nearly a quarter of its market cap after the company announced that the FDA placed a clinical hold on studies of elivaldogene autotemcel designed
Seekingalpha · 08/09 16:01
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 08/05 20:31
Insider Trends: Insider Purchase of Mustang Bio Stock Prolongs 90-Day Positive Trend
MT Newswires · 08/05 16:30
Mustang Bio's Gene Therapy For Genetic Immunodeficiency Receives European PRIME Tag
Benzinga · 08/02 14:31
BRIEF-Mustang Bio Receives European Medicines Agency Prime Designation For Mb-107 To Treat X-Linked Severe Combined Immunodeficiency In Newly Diagnosed Infants
reuters.com · 08/02 12:29
Mustang Bio Reports Received European Medicines Agency PRIME Designation For MB-107 To Treat X-Linked Severe Combined Immunodeficiency In Newly-Diagnosed Infants
Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for
Benzinga · 08/02 12:18
Mustang Bio gets EMA Priority Medicines status for bubble boy disease treatment
Mustang Bio (NASDAQ:MBIO) announces that the European Medicines Agency (EMA) has granted Priority Medicines (“PRIME”) designation to MB-107 for the treatment of X-linked severe combined immunodeficiency (“XSCID”) in newly diagnosed
Seekingalpha · 08/02 12:08
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
WORCESTER, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologi...
GlobeNewswire · 08/02 12:00
European Drug Regulator Adds Priority Tag to Mustang Bio's MB-107 in Rare Genetic Disorder in Infants
MT Newswires · 08/02 11:23
15 Best Penny Stocks to Buy Now
In this article, we discuss the 15 best penny stocks to buy now. If you want to skip our detailed analysis of these companies, go directly to the 5 Best Penny Stocks to Buy Now. Many novice investors are bullish on penny stocks with growth potential for ca...
Insider Monkey · 07/14 13:11
Mustang Bio Shareholders Increase Authorized Common Stock by 25 Million Shares
MT Newswires · 06/22 16:57
BRIEF-Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive
reuters.com · 06/17 12:04
Here's Why We're Not Too Worried About Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 06/15 08:32
Webull provides a variety of real-time MBIO stock news. You can receive the latest news about Mustang Bio through multiple platforms. This information may help you make smarter investment decisions.
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).